Loading
Injecting immune-activating agents into a single tumour, plus a small dose of radiation, can teach the immune system to attack tumours elsewhere in the body.
The in situ vaccine combination of Flt3L to recruit dendritic cells, low-dose radiotherapy to release antigen, and a TLR3 agonist to mature the dendritic cells produced systemic regressions in indolent lymphoma in a phase 1/2 at Mount Sinai. The approach needs no antigen identification and no manufacturing, and has never been properly tested in solid tumours where antigen release by radiotherapy is well characterised.
Shares Abscopal effect, Immunogenic cell death, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy.
Shares Abscopal effect, Immunogenic cell death, Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Cold tumours and the immunosuppressive microenvironment.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy.
Shares Abscopal effect, Immunogenic cell death, STING & innate immune agonists, SBRT / SABR (stereotactic radiotherapy).
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, No one can predict who responds to immunotherapy.
Shares Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs, Hot vs cold tumours, Cold tumours and the immunosuppressive microenvironment, Immune checkpoint inhibitors.